More Evidence for Efficacy, Safety of First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer
According to results from the phase 3b MAURIS study, first-line atezolizumab plus carboplatin and etoposide demonstrated efficacy and safety in a broad population of patients with extensive-stage small cell lung cancer (ES-SCLC).
As reported in IMpower133, “atezolizumab combined to carboplatin and etoposide prolonged survival,” stated Floriana Morgillo, MD, University of Campania, Naples, Italy, and coauthors. The current data are final results from the MARIUS study which examined the efficacy and safety of atezolizumab plus chemotherapy within the same disease state, but “in a patient population with broader inclusion criteria.”
In this open-label study, researchers enrolled 155 previously untreated patients with ES-SCLC to receive 1200 mg of atezolizumab plus carboplatin and etoposide once every 21 days for 4 to 6 cycles followed by maintenance atezolizumab once every 3 weeks. Primary end points included overall survival (OS), progression-free survival (PFS), and safety.
At analysis, the median OS was 10.6 months with OS rates of 45.5% at 1 year, 31% at 1.5 years, 17.1% at 2 years, and 14.5% at 3 years. The median PFS was 5.5 months. Serious adverse events occurred in 38.3% of patients and treatment-related serious adverse events occurred in 21.4% of patients. Immune-mediated treatment-emergent adverse events occurred in 26.6% of patients. Grade 3/4 immune-mediated adverse events were associated with mortality (hazard ratio 0.36).
As Morgillo et al concluded, “this study showed consistent findings with the IMpower133 trial on the safety and efficacy of atezolizumab plus chemotherapy in first-line treatment of ES-SCLC.”
Source:
Morgillo F, Del Signore E, Bria E, et al. The Italian mauris phase IIIB trial of atezolizumab plus carboplatin and etoposide for patients with newly diagnosed extensive-stage small cell lung cancer: 3-year end-of-study results. Clin Lung Cancer. Published online: July 8, 2025. doi: 10.1016/j.cllc.2025.07.003
